Calcium channel blockers (CCBs) and angiotensin II receptor blockers (ARBs) may be associated with a reduced risk of dementia, according to a systematic review and network meta-analysis conducted by researchers from the Netherlands.
Use of the antipsychotic drug pimavanserin led to a substantial reduction in psychosis symptoms in individuals with dementia regardless of severity or subtype, according to the results of the HARMONY trial presented at AAIC 2020.
A new blood test for plasma P-tau217* accurately differentiates Alzheimer's disease (AD) from other neurodegenerative diseases — showing promise as a blood-based biomarker for early detection of AD, according to a study presented at the AAIC 2020 Meeting.
Risk factors for Alzheimer’s disease (AD) may be present as early as adolescence and young adulthood, data presented at AAIC 2020 have shown, highlighting the importance of addressing these factors early in the fight against AD and other dementias.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Pharmacist - Malaysia digital copy today!
Interim results of REGENERATE* trial highlight the ability of experimental noninvasive tests to evaluate treatment response in adults with NASH** and advanced liver fibrosis who are receiving obeticholic acid (OCA).
The combination of pitavastatin and fenofibrate appears to have superior effect on non-high-density lipoprotein cholesterol (non–HDL-C), as well as other lipids, compared with a statin alone in high-risk patients with mixed dyslipidemia, according to a study.